

Alameda Alliance for Health
1240 South Loop Road
Alameda, CA 94502

Oakland/Hayward Conference Rooms
*To arrange public building access, please
contact Ashley Ragadio at 510.373.5731*

AGENDA

| ITEM | DESCRIPTION | TIME | VOTE | | | | | | | | | | | | | | | | | | | | | | |
|---|---|-----------------------------|---------|-------------------|--|-------------------|--|--------------|--|--------------|--|------------|--|------------------|--|---------------------------------------|--|---------------------------|--|----------------------------------|--|---|--|--------|-----------------------------|
| I) | Call to order <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <ul style="list-style-type: none"> Agenda Overview | 2 min | - | | | | | | | | | | | | | | | | | | | | | | |
| II) | Informational Updates <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <ul style="list-style-type: none"> DHCS Audit Update Budget Plan for FY 2020-2021 <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i> <ul style="list-style-type: none"> PerformRX Delegation Audit Pharmacy Cost Containment Strategy Updates | 15min | - | | | | | | | | | | | | | | | | | | | | | | |
| III) | Review/ Approval of previous meeting minutes <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i> <ul style="list-style-type: none"> P&T Meeting Minutes from March 12th, 2019 | 2 min | V | | | | | | | | | | | | | | | | | | | | | | |
| IV) | Pharmacy Utilization Reports (Quarter 1) <i>Helen Lee, PharmD MBA, Senior Pharmacy Director - Alameda Alliance</i> <ul style="list-style-type: none"> Top 50 Drugs by Cost Top 100 PA Reviewed Drugs | | | | | | | | | | | | | | | | | | | | | | | | |
| | Consent Agenda <i>Natalee Felten, PharmD, Pharmacist, PerformRx</i> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i> <i>(All matters listed on the Consent Calendar are to be approved with one motion unless a member of the P&T Committee removes an item for separate action. Any consent calendar item for which separate action is requested shall be heard as the next Agenda item in closed session.)</i> | | | | | | | | | | | | | | | | | | | | | | | | |
| | <table border="1"> <thead> <tr> <th>Monograph/Class Reviews/MRG</th> <th>Changes</th> </tr> </thead> <tbody> <tr> <td>Sucraid Monograph</td> <td> <ul style="list-style-type: none"> No changes </td> </tr> <tr> <td>Ridaura Monograph</td> <td> <ul style="list-style-type: none"> No changes </td> </tr> <tr> <td>Corlanor MRG</td> <td> <ul style="list-style-type: none"> No changes </td> </tr> <tr> <td>Daliresp MRG</td> <td> <ul style="list-style-type: none"> No changes </td> </tr> <tr> <td>Uloric MRG</td> <td> <ul style="list-style-type: none"> No changes </td> </tr> <tr> <td>Levalbuterol MRG</td> <td> <ul style="list-style-type: none"> No changes </td> </tr> <tr> <td>Nutritional formulas, infant formulas</td> <td> <ul style="list-style-type: none"> No changes </td> </tr> <tr> <td>Long-acting basal insulin</td> <td> <ul style="list-style-type: none"> No changes </td> </tr> <tr> <td colspan="2">Interim Formulary changes</td> </tr> <tr> <td colspan="2"> <ul style="list-style-type: none"> See p. XX in packet </td> </tr> </tbody> </table> | Monograph/Class Reviews/MRG | Changes | Sucraid Monograph | <ul style="list-style-type: none"> No changes | Ridaura Monograph | <ul style="list-style-type: none"> No changes | Corlanor MRG | <ul style="list-style-type: none"> No changes | Daliresp MRG | <ul style="list-style-type: none"> No changes | Uloric MRG | <ul style="list-style-type: none"> No changes | Levalbuterol MRG | <ul style="list-style-type: none"> No changes | Nutritional formulas, infant formulas | <ul style="list-style-type: none"> No changes | Long-acting basal insulin | <ul style="list-style-type: none"> No changes | Interim Formulary changes | | <ul style="list-style-type: none"> See p. XX in packet | | 20 min | V <i>(on each topic)</i> |
| Monograph/Class Reviews/MRG | Changes | | | | | | | | | | | | | | | | | | | | | | | | |
| Sucraid Monograph | <ul style="list-style-type: none"> No changes | | | | | | | | | | | | | | | | | | | | | | | | |
| Ridaura Monograph | <ul style="list-style-type: none"> No changes | | | | | | | | | | | | | | | | | | | | | | | | |
| Corlanor MRG | <ul style="list-style-type: none"> No changes | | | | | | | | | | | | | | | | | | | | | | | | |
| Daliresp MRG | <ul style="list-style-type: none"> No changes | | | | | | | | | | | | | | | | | | | | | | | | |
| Uloric MRG | <ul style="list-style-type: none"> No changes | | | | | | | | | | | | | | | | | | | | | | | | |
| Levalbuterol MRG | <ul style="list-style-type: none"> No changes | | | | | | | | | | | | | | | | | | | | | | | | |
| Nutritional formulas, infant formulas | <ul style="list-style-type: none"> No changes | | | | | | | | | | | | | | | | | | | | | | | | |
| Long-acting basal insulin | <ul style="list-style-type: none"> No changes | | | | | | | | | | | | | | | | | | | | | | | | |
| Interim Formulary changes | | | | | | | | | | | | | | | | | | | | | | | | | |
| <ul style="list-style-type: none"> See p. XX in packet | | | | | | | | | | | | | | | | | | | | | | | | | |

- Contraceptives- (condoms, diaphragms, gels, foams) class review
- Triptans class review
- Sucraid monograph
- Ridaura monograph
- Pharmacy Policies & Procedures Updates
 - RX-002 Prior Authorization Review Process
 - RX-008 PBM Delegated Audit Oversight
 - RX-006 Pharmacy Services Staff Description
 - RX-010 Drug Utilization Management
 - RX-011 Decision and Notification Requirements

The following materials will be discussed during Section VII - Medication Request Guidelines on page. **XX**

- Angiotensin II receptor blocker and renin inhibitor medications
- Corlanor
- Daliresp
- Uloric
- Claravis, Myorisan, Zenatane (isotretinoin), Absorica (isotretinoin)
- Levalbuterol (Xopenex/Xopenex HFA)
- NUTRITIONAL FORMULAS, INFANT FORMULAS: STC C5F, C5C
- Tretinoin (Retin-A) gel or cream
- Renagel and Renvela (sevelamer)
- Non-formulary & PA Required Medications Without Drug-Specific Criteria
- Long-Acting Basal Insulin
- Fenofibrates
- Anti-Inflammatory Ophthalmic Agents
- Central Nervous System Stimulants/ ADHD medications
- Agents for Atopic Dermatitis Guidelines
- Cholinesterase Inhibitors
- PCSK9 inhibitors

ADJOURN TO CLOSED SESSION *(Pursuant to California Government Code Title 5, §54954.5(h))*

Discussion will Concern: Review and Recommendations to changes to the AAH Formulary and utilization management for selected drug classes
Estimated Date of Public Disclosure: June 2019 (formulary changes only; no trade secrets will be disclosed).

V) New Business

Natalee Felten, PharmD, Pharmacist, PerformRx

- Januvia/ Janumet change of formulary status & ADA 2019 guidelines prescriber update
- Formulary, step therapy required *For drugs without specific criteria guideline

Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda

Ramon Tran Tang, PharmD, Pharmacist, Alameda

- Opioid Program Quantity Limit and Day Supply update

60 min

V
(on each
topic)

Class Reviews, Monographs, and Recommendations

Natalee Felten, PharmD, Pharmacist, PerformRx

Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance

1. Triptans
2. Anticonvulsants
3. Biologic DMARDs
4. Potassium removing agents
5. Multiple Sclerosis
6. Contraceptives- (condoms, diaphragms, gels, foams)
7. Sucraid monograph
8. Ridaura monograph
9. Hemlibra monograph

RECONVENE IN OPEN SESSION

| ITEM | DESCRIPTION | TIME | VOTE |
|--------------|--|--------|------|
| VI) | Summary of Closed Session <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i> | 2 min | - |
| VII) | Medication Request Guidelines <i>Natalee Felten, PharmD, Pharmacist, PerformRx</i> | | |
| | <ol style="list-style-type: none"> 1. Angiotensin II receptor blocker and renin inhibitor medications 2. Corlanor 3. Furosemide oral solution 4. Daliresp 5. Emflaza 6. Uloric (febuxostat) 7. Claravis, Myorisan, Zenatane (isotretinoin), Absorica (isotretinoin) 8. Levalbuterol (Xopenex/Xopenex HFA) 9. NUTRITIONAL FORMULAS, INFANT FORMULAS: STC C5F, C5C 10. Tretinoin (Retin-A) gel or cream 11. Renagel and Renvela (sevelamer) 12. Non-formulary & PA Required Medications Without Drug-Specific Criteria 13. Long-Acting Basal Insulin 14. Criteria for long-acting opioids 15. Fenofibrates 16. Movement Disorders 17. Drugs for Gender Dysphoria For Less Than 21 Years Old 18. Drugs for Gender Dysphoria For At Least 21 Years Old 19. Anti-Inflammatory Ophthalmic Agents 20. Central Nervous System Stimulants/ ADHD medications 21. Agents for Atopic Dermatitis Guidelines 22. Cholinesterase Inhibitors 23. PCSK9 inhibitors 24. Diabetes Medications | 15 min | V |
| VIII) | Interim Changes (Consent Agenda) <i>Natalee Felten, PharmD, Pharmacist, PerformRx</i> | 0 min | - |
| IX) | Old Business <i>Ketotifen vs. olopatadine analysis</i> | 3 min | |
| X) | Informational Updates on New Developments in Pharmacy <i>Natalee Felten, PharmD, Pharmacist, PerformRx</i> | 5 min | - |
| | <ul style="list-style-type: none"> • New Product Review | | |

| | | |
|------------------------------|-------|---|
| XI) Public Comment | 2 min | - |
| XII) Adjournment | - | - |
| • P&T Committee Member Forms | | |

| ACTION / FOLLOW-UP ITEMS | | |
|---------------------------------|-----------------|--------------------|
| ITEM | DUE DATE | RESPONSIBLE |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

| FUTURE P&T MEETINGS | |
|---------------------------------|-----------------------------------|
| NEXT MEETING | 2019 P&T MEETINGS |
| September 24 th 2019 | September 24 th , 2019 |
| | December 17 th , 2019 |

The Alameda Alliance for Health Pharmacy & Therapeutics Committee welcomes you to its meetings and your interest is appreciated. If you wish to speak on a matter on the agenda, you will have the opportunity to do so in the order determined by the Chair. If you wish to speak on a matter not on the agenda, please wait until the Chair asks for public comments at the end of the regular agenda. Please be brief and limit your comments to the specific subject under discussion.

Note: Only matters within the jurisdiction of the Alameda Alliance for Health Pharmacy & Therapeutics Committee may be addressed. If necessary, the Chair may limit the total time to be devoted to public comment on any item, and the time allotted to individual speakers, to ensure sufficient time for the consideration of all matters on the agenda.

This meeting is wheelchair accessible. Please contact Helen Lee at 510-747- 6241 or hlee@alamedaalliance.org at least 72 hours before the meeting to request agenda materials in an alternative format, or any other reasonable disability-related accommodations or services that may be necessary for you to participate in and enjoy the benefits of the meeting.